Figure 3.
DLGAP1-AS1 accelerated the ADR-resistance of BC cells. (a) Loss (sh-DLGAP1-AS1) and gain (DLGAP1-AS1 overexpression) of function experiments were performed in ADR-resistance BC cells (MCF-7/ADR). (b) CCK8 assay was performed for the proliferative ability of lncRNA DLGAP1-AS1 on MCF-7/ADR cells. (c) ADR sensitivity analysis was e carried out using the CCK8 assays to detect the IC50 of ADR for BC cells in MCF-7/ADR cells transfected with DLGAP1-AS1 knockdown and DLGAP1-AS1 overexpression. (d) In vivo mice assays were performed to illustrate the in vivo tumor growth ability of MCF-7/ADR cells. *P < 0.05, **P < 0.01 vs control group